News Headlines Article

Study weighs debt financing for pricey breakthrough drugs
Modern Healthcare

The emergence of new specialty breakthrough medications has come with a hefty price tag that may demand alternative financing approaches to ensure they remain accessible to patients, a new analysis suggests.Researchers at RAND Corp. propose health providers could use borrowing instruments such as bonds, mortgages or issue lines of credit to pharmaceutical companies that make such specialty drugs such as Gilead’s Sovaldi for hepatitis C, where it can cost more than $80,000 to complete a typical 12-week course of treatment.